Review
Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion
Affiliations
- PMID: 8809652
Item in Clipboard
Review
Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion
J Infus Chemother.
1996 Spring.
Abstract
In this review, the clinical pharmacology of high-dose doxorubicin is examined, and the pharmacokinetics of infusional doxorubicin at standard and high dose are compared. The data developed here, including recent clinical trials of high-dose infusional doxorubicin, demonstrate the safety and efficacy of doxorubicin administration at doses > or = 150 mg/m2 for patients with breast cancer and strongly suggest that the utility of this drug can be substantially increased with appropriate hematopoietic support.
Similar articles
-
Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).Anticancer Res. 2000 Jan-Feb;20(1B):485-91. Anticancer Res. 2000. PMID: 10769710 Clinical Trial.
-
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.Semin Oncol. 1996 Oct;23(5 Suppl 11):16-22. Semin Oncol. 1996. PMID: 8893894 Clinical Trial.
-
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.Cancer Chemother Pharmacol. 2004 Sep;54(3):241-8. doi: 10.1007/s00280-004-0803-4. Epub 2004 Jun 2. Cancer Chemother Pharmacol. 2004. PMID: 15173955 Clinical Trial.
-
Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.Oncologist. 2005 Mar;10(3):205-14. doi: 10.1634/theoncologist.10-3-205. Oncologist. 2005. PMID: 15793224 Review.
-
High-dose infusional 5-FU in the treatment of advanced colorectal cancer: a summary of the European experience.J Infus Chemother. 1996 Summer;6(3):145-8. J Infus Chemother. 1996. PMID: 9229327 Review.
Cited by
-
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome.Br J Cancer. 2001 Jun 15;84(12):1591-8. doi: 10.1054/bjoc.2001.1835. Br J Cancer. 2001. PMID: 11401310 Free PMC article. Clinical Trial.
-
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.Pediatrics. 2012 Dec;130(6):1003-11. doi: 10.1542/peds.2012-0727. Epub 2012 Nov 19. Pediatrics. 2012. PMID: 23166343 Free PMC article. Clinical Trial.
-
Role of SLC transporters in toxicity induced by anticancer drugs.Expert Opin Drug Metab Toxicol. 2020 Jun;16(6):493-506. doi: 10.1080/17425255.2020.1755253. Epub 2020 Apr 26. Expert Opin Drug Metab Toxicol. 2020. PMID: 32276560 Free PMC article. Review.
-
Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.Med Oncol. 2005;22(3):257-67. doi: 10.1385/MO:22:3:257. Med Oncol. 2005. PMID: 16110137 Clinical Trial.
-
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.J Transl Med. 2016 Mar 8;14:67. doi: 10.1186/s12967-016-0814-z. J Transl Med. 2016. PMID: 26952093 Free PMC article.